FY2024 Earnings Estimate for UNH Issued By Cantor Fitzgerald

UnitedHealth Group Incorporated (NYSE:UNH) – Equities researchers at Cantor Fitzgerald lifted their FY2024 EPS estimates for UnitedHealth Group in a research report issued to clients and investors on Monday, December 9th. Cantor Fitzgerald analyst S. James now expects that the healthcare conglomerate will earn $27.60 per share for the year, up from their previous estimate of $27.56. Cantor Fitzgerald has a “Overweight” rating and a $644.00 price target on the stock. The consensus estimate for UnitedHealth Group’s current full-year earnings is $27.63 per share.

UnitedHealth Group (NYSE:UNH) last posted its quarterly earnings results on Tuesday, October 15th. The healthcare conglomerate reported $7.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.00 by $0.15. UnitedHealth Group had a net margin of 3.63% and a return on equity of 26.37%. The firm had revenue of $100.82 billion for the quarter, compared to analyst estimates of $99.14 billion. During the same period in the prior year, the firm posted $6.56 earnings per share. The company’s quarterly revenue was up 9.2% compared to the same quarter last year.

Several other brokerages have also weighed in on UNH. Deutsche Bank Aktiengesellschaft increased their price objective on shares of UnitedHealth Group from $595.00 to $625.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. StockNews.com raised shares of UnitedHealth Group from a “hold” rating to a “buy” rating in a research report on Monday. Stephens upped their price target on shares of UnitedHealth Group from $605.00 to $675.00 and gave the company an “overweight” rating in a research note on Thursday, December 5th. TD Cowen upped their price target on shares of UnitedHealth Group from $601.00 to $609.00 and gave the company a “buy” rating in a research note on Friday, October 18th. Finally, Truist Financial restated a “buy” rating and issued a $625.00 price target (down from $640.00) on shares of UnitedHealth Group in a research note on Wednesday, October 16th. Three research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $626.84.

UnitedHealth Group Stock Performance

NYSE UNH opened at $565.39 on Tuesday. The firm has a market capitalization of $520.31 billion, a P/E ratio of 36.82, a price-to-earnings-growth ratio of 1.61 and a beta of 0.58. The firm’s fifty day moving average price is $586.36 and its two-hundred day moving average price is $559.39. UnitedHealth Group has a 1 year low of $436.38 and a 1 year high of $630.73. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.74.

UnitedHealth Group Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 17th. Stockholders of record on Monday, December 9th will be paid a $2.10 dividend. The ex-dividend date is Monday, December 9th. This represents a $8.40 annualized dividend and a dividend yield of 1.49%. UnitedHealth Group’s dividend payout ratio is currently 54.72%.

Institutional Trading of UnitedHealth Group

Several hedge funds have recently modified their holdings of UNH. International Assets Investment Management LLC increased its stake in shares of UnitedHealth Group by 78,814.4% in the 3rd quarter. International Assets Investment Management LLC now owns 5,296,737 shares of the healthcare conglomerate’s stock valued at $3,096,896,000 after acquiring an additional 5,290,025 shares in the last quarter. Lone Pine Capital LLC acquired a new stake in UnitedHealth Group in the 2nd quarter valued at $480,903,000. Dimensional Fund Advisors LP grew its position in UnitedHealth Group by 30.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,816,254 shares of the healthcare conglomerate’s stock valued at $1,942,956,000 after purchasing an additional 880,183 shares during the period. Baillie Gifford & Co. grew its position in UnitedHealth Group by 1,125.4% in the 2nd quarter. Baillie Gifford & Co. now owns 894,006 shares of the healthcare conglomerate’s stock valued at $455,281,000 after purchasing an additional 821,050 shares during the period. Finally, Accredited Investors Inc. grew its position in UnitedHealth Group by 9,235.4% in the 3rd quarter. Accredited Investors Inc. now owns 784,924 shares of the healthcare conglomerate’s stock valued at $458,929,000 after purchasing an additional 776,516 shares during the period. Institutional investors own 87.86% of the company’s stock.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.